These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

48 related articles for article (PubMed ID: 27088596)

  • 1. Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.
    Costa-Cabral S; Brough R; Konde A; Aarts M; Campbell J; Marinari E; Riffell J; Bardelli A; Torrance C; Lord CJ; Ashworth A
    PLoS One; 2016; 11(4):e0154007. PubMed ID: 27088596
    [No Abstract]   [Full Text] [Related]  

  • 2. Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.
    Costa-Cabral S; Brough R; Konde A; Aarts M; Campbell J; Marinari E; Riffell J; Bardelli A; Torrance C; Lord CJ; Ashworth A
    PLoS One; 2017; 12(4):e0176578. PubMed ID: 28426773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correction: Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.
    Costa-Cabral S; Brough R; Konde A; Aarts M; Campbell J; Marinari E; Riffell J; Bardelli A; Torrance C; Lord CJ; Ashworth A
    PLoS One; 2018; 13(10):e0206729. PubMed ID: 30365555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of vaccination with mutant KRAS peptides on rat colon carcinogenesis induced by azoxymethane.
    Paulsen JE; Bjørheim J; Røe J; Eide TJ; Alexander J; Gaudernack G
    Anticancer Res; 2002; 22(1A):171-5. PubMed ID: 12017282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cationic lipid-assisted polymeric nanoparticle mediated GATA2 siRNA delivery for synthetic lethal therapy of KRAS mutant non-small-cell lung carcinoma.
    Shen S; Mao CQ; Yang XZ; Du XJ; Liu Y; Zhu YH; Wang J
    Mol Pharm; 2014 Aug; 11(8):2612-22. PubMed ID: 24521262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. STK33 kinase activity is nonessential in KRAS-dependent cancer cells.
    Babij C; Zhang Y; Kurzeja RJ; Munzli A; Shehabeldin A; Fernando M; Quon K; Kassner PD; Ruefli-Brasse AA; Watson VJ; Fajardo F; Jackson A; Zondlo J; Sun Y; Ellison AR; Plewa CA; San MT; Robinson J; McCarter J; Schwandner R; Judd T; Carnahan J; Dussault I
    Cancer Res; 2011 Sep; 71(17):5818-26. PubMed ID: 21742770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lung-cancer chemoprevention by induction of synthetic lethality in mutant KRAS premalignant cells in vitro and in vivo.
    Huang S; Ren X; Wang L; Zhang L; Wu X
    Cancer Prev Res (Phila); 2011 May; 4(5):666-73. PubMed ID: 21543344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells.
    Lamba S; Russo M; Sun C; Lazzari L; Cancelliere C; Grernrum W; Lieftink C; Bernards R; Di Nicolantonio F; Bardelli A
    Cell Rep; 2014 Sep; 8(5):1475-83. PubMed ID: 25199829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status.
    Oliveira C; Westra JL; Arango D; Ollikainen M; Domingo E; Ferreira A; Velho S; Niessen R; Lagerstedt K; Alhopuro P; Laiho P; Veiga I; Teixeira MR; Ligtenberg M; Kleibeuker JH; Sijmons RH; Plukker JT; Imai K; Lage P; Hamelin R; Albuquerque C; Schwartz S; Lindblom A; Peltomaki P; Yamamoto H; Aaltonen LA; Seruca R; Hofstra RM
    Hum Mol Genet; 2004 Oct; 13(19):2303-11. PubMed ID: 15294875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KRAS mutations in lung cancer.
    Karachaliou N; Mayo C; Costa C; Magrí I; Gimenez-Capitan A; Molina-Vila MA; Rosell R
    Clin Lung Cancer; 2013 May; 14(3):205-14. PubMed ID: 23122493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.
    Jänne PA; Shaw AT; Pereira JR; Jeannin G; Vansteenkiste J; Barrios C; Franke FA; Grinsted L; Zazulina V; Smith P; Smith I; Crinò L
    Lancet Oncol; 2013 Jan; 14(1):38-47. PubMed ID: 23200175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the prevalence of KRAS-LCS6 polymorphism (rs61764370) within different tumour types (colorectal, breast, non-small cell lung cancer and brain tumours). A study of the Czech population.
    Uvirova M; Simova J; Kubova B; Dvorackova N; Tomaskova H; Sedivcova M; Dite P
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Sep; 159(3):466-71. PubMed ID: 26077004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drosophila myt1 is the major cdk1 inhibitory kinase for wing imaginal disc development.
    Jin Z; Homola E; Tiong S; Campbell SD
    Genetics; 2008 Dec; 180(4):2123-33. PubMed ID: 18940789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of KRAS codon 12 mutants using a novel DNA-alkylating pyrrole-imidazole polyamide conjugate.
    Hiraoka K; Inoue T; Taylor RD; Watanabe T; Koshikawa N; Yoda H; Shinohara K; Takatori A; Sugimoto H; Maru Y; Denda T; Fujiwara K; Balmain A; Ozaki T; Bando T; Sugiyama H; Nagase H
    Nat Commun; 2015 Apr; 6():6706. PubMed ID: 25913614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A requirement for wild-type Ras isoforms in mutant KRas-driven signalling and transformation.
    Bentley C; Jurinka SS; Kljavin NM; Vartanian S; Ramani SR; Gonzalez LC; Yu K; Modrusan Z; Du P; Bourgon R; Neve RM; Stokoe D
    Biochem J; 2013 Jun; 452(2):313-20. PubMed ID: 23496764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of Cdk1 in the p53-independent abrogation of the postmitotic checkpoint by human papillomavirus E6.
    Zhang W; Liu Y; Zhao N; Chen H; Qiao L; Zhao W; Chen JJ
    J Virol; 2015 Mar; 89(5):2553-62. PubMed ID: 25520504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours.
    Sieben NL; Macropoulos P; Roemen GM; Kolkman-Uljee SM; Jan Fleuren G; Houmadi R; Diss T; Warren B; Al Adnani M; De Goeij AP; Krausz T; Flanagan AM
    J Pathol; 2004 Mar; 202(3):336-40. PubMed ID: 14991899
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Parsons BL; Myers MB
    Per Med; 2013 Mar; 10(2):191-199. PubMed ID: 27867401
    [No Abstract]   [Full Text] [Related]  

  • 19. mTORC1 upregulation via ERK-dependent gene expression change confers intrinsic resistance to MEK inhibitors in oncogenic KRas-mutant cancer cells.
    Komatsu N; Fujita Y; Matsuda M; Aoki K
    Oncogene; 2015 Nov; 34(45):5607-16. PubMed ID: 25703330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Akt mediated ROS-dependent selective targeting of mutant KRAS tumors.
    Iskandar K; Rezlan M; Pervaiz S
    Free Radic Biol Med; 2014 Oct; 75 Suppl 1():S13. PubMed ID: 26461287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.